Real-world data on PRO-CTCAE-assessed symptomatic toxicities in patients receiving palbociclib (PAL) plus endocrine therapy (ET) remain limited. We evaluated the feasibility of longitudinal assessment and characterized symptom profiles in a multicenter prospective cohort study. Patients with HR+/HER2 − metastatic breast cancer receiving PAL plus ET completed paper-based PRO-CTCAE at nine scheduled time points over 6 months. PRO-CTCAE availability was evaluated using the entire analysis population as a fixed denominator. Within-patient changes in general pain, joint pain, and fatigue were assessed, and longitudinal changes in severity were evaluated using cumulative link mixed models (CLMMs). Additional CLMMs examined differences in symptom trajectories between aromatase inhibitor (AI) and fulvestrant (FUL) groups after adjustment for baseline symptom severity, treatment line, and age. Among 593 patients in the original cohort, 414 with baseline paper-based PRO-CTCAE assessments were analyzed. PRO-CTCAE availability was 100
Volumetric breast density (VBD) is influenced by age, body mass index (BMI), and reproductive factors, yet the shape of the age–VBD association and age-specific VBD distributions in Japanese women remain incompletely characterized. We examined the associations of age, BMI, menopausal status, and parity with software-derived VBD and characterized age-specific VBD distributions, including the proportion of women with VBD ≥ 7.5
This study aimed to develop and validate a predictive model integrating dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) kinetic features and digital breast tomosynthesis (DBT) texture features for predicting pathological complete response (pCR) following neoadjuvant chemotherapy (NAC) in patients with triple-negative breast cancer (TNBC). Additionally, its predictive performance was compared with that of single-modality models. A total of 360 patients with pathologically confirmed TNBC who received NAC between January 2022 and December 2025 were retrospectively and consecutively collected. Patients were randomly allocated to a training set (n = 252) and a validation set (n = 108) at a 7:3 ratio. Pre-NAC DCE-MRI kinetic and DBT texture features were extracted. After feature selection using least absolute shrinkage and selection operator (LASSO) regression, DCE-MRI and DBT radiomics scores (Rad-scores) were constructed. A nomogram prediction model was then developed using multivariable logistic regression incorporating clinicopathological and laboratory indicators. Model discrimination, calibration, and clinical net benefit were evaluated using the receiver operating characteristic curves, calibration curves, and decision curve analysis, respectively. These results were subsequently compared with those of a clinical-only model and single-modality combined models. The pCR rates in the training and validation sets were 41.67
Pathological response after neoadjuvant chemotherapy is strongly associated with prognosis in breast cancer. However, further prognostic stratification is needed among patients with residual invasive disease because their outcomes vary widely. The six-tier Japanese Breast Cancer Society (JBCS) pathological treatment effect classification provides a graded assessment of histological response in the primary breast tumor, but its prognostic validity has not been sufficiently established in a large cohort. We retrospectively analyzed 1,003 patients with invasive breast cancer who underwent surgery after neoadjuvant chemotherapy at two institutions between 2006 and 2022. Distant recurrence-free survival (DRFS) was evaluated according to the six-tier JBCS classification. Multivariable Cox models incorporating either the six-tier JBCS classification or ypT were adjusted for age, breast cancer subtype, and ypN and compared using the corrected Akaike information criterion (AICc) and Bayesian information criterion (BIC). Exploratory analyses also evaluated simplified classifications. The six-tier JBCS classification significantly stratified DRFS (log-rank P < 0.001). Five-year DRFS increased from 60.6
